Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
The quest for the Grail is beset with challenges.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.